Table 2.
Percentages of TCR-Activated CD4+ and CD8+ T Cells That Synthesized IL-2, IFN-γ, TNF-α, or IL-10 at Pretreatment, After 3 cycles, and After 15 cycles of Lenalidomide Therapy
| Treatment With Lenalidomide | Healthy Subjects n=22 | |||
|---|---|---|---|---|
| Pretreatment n=24 Median (Mean±SEM) |
After 3 Cycles n=24 Median (Mean±SEM) |
After 15 Cycles n=17 Median (Mean±SEM) |
Median (Mean±SEM) | |
| % CD4+IL-2+ | 29.1a (26.6±2.2) | 30.3a (26.9±2.2) | 14.7b (14.2±1.8) | 19.3 (17±1.5) |
| % CD4+IFN-γ+ | 20.2a (18.3±1.7) | 16.4 (17.6±1.3) | 11.4b (12.0±2.7) | 13.4 (13.9±1.8) |
| % CD4+TNF-α+ | 43.9a (39.3±2.9) | 39.7a (29.1±2.3) | 28.5b (26.8±2.9) | 27.8 (26.8±1.8) |
| % CD4+IL-10+ | 2.6a (2.8±0.3) | 1.9a,c (2.2±0.2) | 1.7a (2.0±0.4) | 4.7 (5.4±0.5) |
| % CD8+IL-2+ | 6.7 (7.9±1.4) | 8.7 (9.8±1.5) | 2.0a,b (2.8±0.6) | 8.0 (8.0±1.1) |
| % CD8+IFN-γ+ | 12.7 (14.4±1.8) | 20.1c (19.1±1.7) | 11.3 (13.2±2.3) | 13.6 (15.4±1.5) |
| % CD8+TNF-α+ | 13.9 (15.9±2.1) | 17.1 (18.7±1.9) | 10.6a,b (11.2±1.4) | 16.7 (7.4±1.6) |
| % CD8+IL-10+ | 1.0a (1.2±0.1) | 1.0a (1.2±0.2) | 1.4a (1.7±0.4) | 3.8 (4.9±0.7) |
SEM indicates standard error of the mean.
There were significant differences between CLL patients and healthy subjects with respect to cytokine synthesis by TCR-activated CD4+ or CD8+ T cells.
There were significant changes between the median percentages of TCR-activated CD4+ or CD8+ T cells producing cytokines by CLL patients after 15 cycles of treatment versus their respective levels after 3 cycles of treatment.
There were significant changes between the median percentages of TCR-activated CD4+ or CD8+ T cells producing cytokines by CLL patients after 3 cycles of treatment versus their respective levels before treatment.